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Edited by Jesus AvilaAbstract Impaired functioning of the proteasome pathway is
one of the molecular mechanism underlying neurodegenerative
changes in Alzheimer’s disease. In this study, we report that
dysfunction of the proteasome pathway in astroglial cells leads
to decreased survival and dysregulation of chemokines by diﬀer-
ential regulation of the nuclear factor kappa B and c-jun N-ter-
minal kinase (JNK) pathways. We further demonstrated that
proteasome inhibition augmented interleukin-1 b- and tumor
necrosis factor-a-induced activation of the IjBa kinase and
MKK4/JNK/c-Jun pathway along with TAK1 activation. These
results suggest that impaired function of the proteasome pathway
may potentiate the immuno-pathologic role of secondarily acti-
vated astrocytes in the brain.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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One of the prominent features of the neurodegeneration is
the accumulation of toxic protein aggregates inside and outside
neurons and glial cells. Protein aggregation can result from the
increased production of abnormal proteins or the reduced
activity of proteolytic systems [1]. Impaired function of the
proteasome pathway has also been documented in chronic,Abbreviations: AD, Alzheimer’s disease; AP-1, activator protein-1;
IjBa, inhibitor kappa B alpha; IKK, IjBa kinase; IL, interleukin;
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NF-jB, nuclear factor kappa B; PARP, poly(ADP-ribose) polymerase;
RPA, RNase protection assay; TNF-a, tumor necrosis factor-alpha;
TRAF, TNF receptor associated factor
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doi:10.1016/j.febslet.2007.08.065non-familial neurodegenerative disorders, such as Alzheimer’s
disease (AD) and Parkinson’s disease [2–4].
Recent studies implicate controversial roles of the protea-
some pathway on immune responses [5,6]. Inhibition of this
pathway has been shown to suppress immune responses,
mainly through a blockade of the activation of the nuclear
factor kappa B (NF-jB) pathway induced by proinﬂammatory
cytokines [7,8]. On the other hand, a paradoxical induction of
inﬂammatory responses by inhibition of the proteasome path-
way has also been reported [5,6]. In this study, we investigated
the eﬀect of the proteasome pathway on interleukin-1b (IL-1b)
and tumor necrosis factor-a (TNF-a) signaling in human
astrocytes, and tried to understand how secondarily activated
astrocytes would mediate immune responses in vivo under
the conditions of the compromised proteasome pathway in
aging or AD brains.2. Materials and methods
2.1. Cell culture and reagents
Primary human fetal astrocytes and CRT-MG astrocytoma cells
were maintained as previously described [9,10]. Human recombinant
IL-1b and TNF-a were purchased from R&D Systems (Minneapolis,
MN, USA). The proteasome inhibitors, MG-132 and lactacystin,
and non-speciﬁc caspase inhibitor, z-VAD-Fmk, were purchased from
Calbiochem (La Jolla, CA, USA). Tetramethylrhodamine ethyl ester
(TMRE) was purchased from Molecular Probe (Eugene, OR, USA).2.2. RNase protection assay (RPA)
The linearized human chemokine multi-probe set (PharMingen, San
Diego, CA, USA) was transcribed in vitro with T7 RNA polymerase,
resulting in anti-sense RNA probes. RPA was carried out as previously
described [11]. Values for chemokine mRNA levels were normalized to
those of GAPDH mRNA levels for each experimental condition.2.3. ELISA and western blot analysis
Concentrations of IL-8 and monocyte chemoattractant protein-1
(MCP-1) in the supernatants were determined using dual-antibody
solid phase ELISA (Biosource International, Camarillo, CA, USA).
For western blot analysis, cell lysates were electrophoresed in 12%
SDS–PAGE and then transferred to nitrocellulose and probed with
antibodies. Antibodies speciﬁc for mitogen kinase kinase (MKK),
phospho-MKK4 (Ser257/Thr261), JNKs (p46 and p54), phospho-JNKs
(Thr183/Try185), c-Jun, phospho-c-Jun (Ser73), IjBa kinase (IKK),
phospho-IKKa/b (Ser176/180), inhibitor kappa B alpha (IjBa), phos-
pho-IjBa (Ser32/36), and caspase 3 were purchased from Cell Signaling
(Beverly, MA, USA). Antibodies speciﬁc for TRAF2 and TRAF6 wereblished by Elsevier B.V. All rights reserved.
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The blots were developed by chemiluminescence (AbFrontier, Seoul,
Korea).
2.4. Measurement of DNA binding activity of NF-jB and activator
protein-1 (AP-1)
Nuclear extracts were obtained as described previously [9]. Nuclear
extracts (5 lg) were assayed for the binding activity of p65/c-Rel
(NF-jB) and c-jun (AP-1) using the TransAM NF-jB and AP-1 assay
kit (ActiveMotif, Carlsbad, CA, USA) according to the manufacturer’s
manual.
2.5. Detection of cell death
Cells were washed twice with PBS, trypsinized, suspended in 200 lL
of binding buﬀer, and stained with 0.5 ng of Annexin V-FITC (Pharm-
ingen, San Diego, CA, USA) and 2.5 ng of propidium iodide (PI) as
previously described [9,11]. Cell death was deﬁned as cell fractions
stained with Annexin V and/or PI. Mitochondrial transmembrane
potential (DWm) was assessed after staining with 2 lmol/L of TMRE.
2.6. Statistical analysis
Data are presented as mean ± S.D. Levels of signiﬁcance for com-
parisons between two independent samples were determined using Stu-
dent’s t-test distribution. Statistical analyses between more than threeFig. 1. Divergent eﬀects of proteasome inhibition on IL-1b- and TNF-a-med
absence or presence of MG-132 for 2 h, then treated with IL-1b or TNF-a
expression. (B) CRT-MG cells were incubated in the absence or presence
additional 24h, and the supernatant was assayed for MCP-1 or IL-8 protein b
sample are indicated by asterisk (P < 0.05) and double asterisks (P < 0.01
lactacystin (1 lmol/L) for 2 h, treated with IL-1b (0.4 ng/ml) or TNF-a (1 ng/
or IL-8 protein. (D) Human primary fetal astrocytes were incubated in the ab
with IL-1b or TNF-a for an additional 24 h, and the supernatant was assayed
untreated sample are indicated by asterisk (P < 0.05) and double asterisks (Psamples were performed by ANOVA with Tukey’s honest signiﬁcant
diﬀerence post hoc test applied to signiﬁcant main eﬀects or interac-
tions (SPSS 12.0K for Windows, SPSS, Chicago, IL, USA).3. Results
3.1. Eﬀect of proteasome inhibition on IL-1b- and TNF-a-
mediated chemokine expression
Treatment with IL-1b and TNF-a induced a robust mRNA
expression of MCP-1 and IL-8, and weakly induced that of IP-
10 and RANTES in astroglial cells (Fig. 1A). Preincubation
with MG-132 completely suppressed IL-1b- and TNF-a-in-
duced mRNA expression of MCP-1, RANTES, and IP-10;
however, IL-8 was enhanced by the same treatment (Fig. 1A,
lanes 5 and 6). Compatible results were obtained for protein
expression as measured by ELISA (Fig. 1B). We could also ob-
serve a similar pattern of chemokine gene regulation by an-
other proteasome inhibitor, lactacystin (Fig. 1C). The
divergent eﬀect on IL-8 expression was also conﬁrmed in
human primary astrocytes (Fig. 1D).iated chemokine expression. (A) CRT-MG cells were incubated in the
for an additional 6 h, and total RNA was analyzed for chemokine
of MG-132 (1 lmol/L) for 2 h, treated with IL-1b or TNF-a for an
y ELISA. Values signiﬁcantly diﬀerent from the value of the untreated
). (C) CRT-MG cells were incubated in the absence or presence of
ml) for an additional 24 h, and the supernatant was assayed for MCP-1
sence or presence of lactacystin or MG-132 (1 lmol/L) for 2 h, treated
for MCP-1 or IL-8. Values signiﬁcantly diﬀerent from the value of the
< 0.01).
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and JNK pathway
To delineate the mechanism responsible for the eﬀect of pro-
teasome inhibitors, activity of transcription factors was exam-
ined using modiﬁed electrophoretic mobility shift assay
(Fig. 2A). Treatment with TNF-a increased the binding activ-
ity of NF-jB in the nuclear extracts. Preincubation with MG-
132 or lactacystin signiﬁcantly suppressed the NF-jB binding
activity induced by TNF-a (Fig. 2A).
To further uncover the mechanisms, the eﬀects of protea-
some inhibitors on the signaling pathways were examined by
immunoblot analysis. Treatment with TNF-a induced IjBa
phosphorylation within 5 min of stimulation, which was imme-
diately followed by degradation of IjBa by 15 min (Fig. 2B
and C). Preincubation of MG-132, as expected, inhibited
TNF-a-induced degradation of IjBa and delayed the time
course of de novo synthesis of IjBa. Treatment with IL-1b
also induced IjBa phosphorylation, and IjBa degradation
was inhibited by the pretreatment of MG-132 in a similar pat-
tern to TNF-a treatment (data not shown). Notably, the pre-
incubation of MG-132 induced a robust and fast
phosphorylation of IjBa within 2 min of TNF-a treatment.
Consistent with the results of IjBa, the combined treatment
of MG-132 and TNF-a markedly enhanced IKK phosphoryla-
tion within 2 min.
We next examined the c-Jun N-terminal kinase (JNK) sig-
naling pathway. Treatment with TNF-a increased the binding
activity of c-jun/AP-1 in the nuclear extracts (Fig. 3A). Protea-
some inhibition, however, increased c-jun/AP-1 binding activ-
ity, which was synergistically augmented by the addition of
TNF-a (Fig. 3A). Consistent with this ﬁnding, preincubation
with MG-132 markedly enhanced the phosphorylation of
MKK4, JNK, and c-Jun induced by TNF-a (Fig. 3B and C).
Treatment with IL-1b also induced a time-dependent phos-Fig. 2. Diﬀerential eﬀect of proteasome inhibition on NF-jB pathway. (A) C
2 h, and treated with TNF-a for an additional 40 min. Values statistically sig
treatment are indicated by asterisk (Tukey post hoc test applied to signiﬁcan
statistically signiﬁcantly diﬀerent from the value for the sample treated with TN
(Tukey post hoc test applied to signiﬁcant eﬀect of group ANOVA F5, 11 =
presence of MG-132 (1 lmol/L) for 2 h, treated with TNF-a for the indic
phosphorylated IjBa and total IjBa was plotted over the time upon TNF-aphorylation of MKK4, JNK and c-jun, which were markedly
augmented by pretreatment with MG-132 (data not shown).
We further investigated the upstream signal responsible for
augmented activation of IKK and MKK4 by proteasome
inhibitors. TAK1 has been recently shown to play an impor-
tant role in proinﬂammatory cytokine-mediated signaling
[12]. As expected, TAK1 was phosphorylated upon TNF-a
or IL-1b stimulation in a time-dependent manner. Pretreat-
ment with MG-132 markedly augmented TNF-a- or IL-1b-in-
duced phosphorylation of TAK1 (Fig. 4). TNF receptor
associated factor (TRAF) proteins, especially TRAF2 and 6,
are known to mediate TNF-a- and IL-1b-mediated phosphory-
lation of TAK1 [12]. TRAFs are then polyubiquitylated and
degraded by the proteasome complexes to prevent the sus-
tained activation of receptor signaling [13–15]. Consistent
with previous reports, the amount of TRAFs decreased upon
TNF-a- and IL-1b stimulation in a time dependent manner,
and the proteasome inhibition suppressed TNF-a- and
IL-1b-induced degradation of TRAFs (Fig. 4).
3.3. Proteasome inhibition induces caspase-dependent apoptotic
cell death
Treatment with IL-1b or TNF-a did not induce cell death in
human astroglial cells; however, preincubation with the pro-
teasome inhibitors induced apoptotic cell death (4-fold
induction) in a dose-dependent manner, although MG-132 or
lactacystin alone had little eﬀect on cell survival (Fig. 5A). In
primary human astrocytes, IL-1b or TNF-a treatment com-
bined with MG-132 or lactacystin also induced apoptotic cell
death, which was abrogated by preincubation with z-VAD-
fmk (Fig. 5B). In combination with MG-132 or lactacystin,
treatment with TNF-a or IL-1b induced proteolytic cleavage
of caspase-3 and poly(ADP-ribose) polymerase (PARP), which
was completely blocked by caspase inhibition (Fig. 5C and D).RT-MG cells were incubated in the absence of presence of MG-132 for
niﬁcantly diﬀerent from the value for the control sample without any
t eﬀect of group ANOVA F5, 11 = 3.3, P = 0.045). (P < 0.001). Values
F-a alone without any pretreatment are indicated by ‘‘sharp character’’
3.3, P = 0.045). (P < 0.01). (B) Cells were incubated in the absence or
ated time points. (C) The relative amount of phosphorylated IKK,
treatment in the absence (dotted line) and presence (line) of MG-132.
Fig. 4. Eﬀect of proteasome inhibition on TRAF proteins and TAK1 phosphorylation. CRT-MG cells were incubated in the absence or presence of
MG-132 for 1 h, and treated with TNF-a (A) or IL-1b (B) for the indicated time points.
Fig. 3. Activation of JNK pathway by proteasome inhibition. (A) CRT-MG cells were incubated in the absence of presence of MG-132 for 2 h, and
treated with TNF-a for an additional 40 min. Values statistically signiﬁcantly diﬀerent from the value for the control sample without any treatment
are indicated by asterisk (Tukey post hoc test applied to signiﬁcant eﬀect of group ANOVA F5, 11 = 20.9, P < 0.001). (P < 0.001). Values statistically
signiﬁcantly diﬀerent from the value for the sample treated with TNF-a alone without any pretreatment are indicated by P values (Tukey post hoc
test applied to signiﬁcant eﬀect of group ANOVA F5, 11 = 20.9, P < 0.001). (B) CRT-MG cells were incubated in the absence or presence of MG-132
(1 lmol/L) for 2 h, treated with TNF-a for the indicated time points. (C) The relative amount of phosphorylated MKK4, phosphorylated JNK and
phosphorylated c-jun was plotted over the time upon TNF-a treatment in the absence (dotted line) and presence (line) of MG-132.
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Our results suggest that proinﬂammatory signals may pro-
voke a lesser degree of induction of inﬂammatory responses
and much enhanced cytotoxicity under impaired conditions
of the proteasome pathway in the CNS (Fig. 6). These may
be of some beneﬁt in the diminution of proinﬂammatory medi-
ators released by activated astrocytes in aging or AD brains;
however, enhanced cytotoxicity of proinﬂammatory cytokines(e.g., IL-1b and TNF-a) may be detrimental to the survival of
neuronal and glial cells. Therefore, the signiﬁcance of these
cytokines and secondarily activated astrocytes in the patho-
genesis of AD should be reconsidered in the context of com-
promised proteasome function [3,16]. However, in this study
we have strictly focused on the eﬀect of proteasome inhibition
in the astroglial cells, further studies including microglial cells
are needed in order to get a possible picture of the in vivo
situation.
Fig. 5. Decreased cell survival by proteasome inhibition. (A) CRT-MG cells were incubated in the absence or presence of lactacystin or MG-132
(1 lmol/L) for 2 h, treated with IL-1b (4 ng/ml) or TNF-a (10 ng/ml) for an additional 24 h, and the cell death was measured. Data are the
mean ± S.D. for quadruplicate samples from two independent experiments. Values signiﬁcantly diﬀerent from the value of the untreated sample are
indicated by asterisk (P < 0.05). (B) Primary cultured human fetal astrocytes were incubated in the absence or presence of z-VAD-fmk (10 lmol/L)
and/or lactacystin or MG-132 for 2 h, treated with IL-1b or TNF-a for an additional 4 h, and the mitochondrial transmembrane potential (DWm) was
measured. (C) Cells were incubated in the absence or presence of MG-132, treated with IL-1b or TNF-a for an additional 6 h, and cell lysates were
examined by immunoblot analysis. The arrowheads indicate the proteolytic products of caspase-3 (17, 19 kDa) and PARP (89 kDa). (D) Cells were
incubated in the absence or presence of z-VAD-fmk and/or lactacystin, and treated with IL-1b or TNF-a for an additional 6 h.
Fig. 6. Proposed role of proteasome pathway on the aspect of proinﬂammatory signaling in astrocytes. The proposed model for the pathophysiologic
roles of the proteasome pathway on the IL-1b and TNF-a signaling in the normal brains (A) or compromised brains (B) were demonstrated. Solid
lines indicate positive inﬂuences while dotted lines do negative ones.
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in vivo correlates well with the potency to inhibit NF-jB acti-
vation and thus provides the rationale to consider these inhib-
itors as potential therapeutic agents for treatment of the
inﬂammatory disorders [7,8,17]. To our surprise, proteasome
inhibition resulted in unexpected increment of IKK phosphor-ylation. Up to this date, the linkage between the proteasome
pathway and signaling pathway responsible for IKK activa-
tion has not been elucidated. Our results also suggest that
the sustained and unopposed activation of the JNK/AP-1
pathway might be responsible for IL-8 gene expression and
increased cell death induced by IL-1b and TNF-a. However,
4696 K. Choi et al. / FEBS Letters 581 (2007) 4691–4696we cannot exclude the possibilities that other unidentiﬁed
pathways may participate in these processes, and activation
of the JNK/AP-1 pathway is just one of the consequences of
proteasome inhibition.
NF-jB and AP-1 are the major transcription factors
involved in IL-8 gene expression, whereas NF-IL-6 plays a
minor role [18]. Our data suggest that NF-jB activation is nec-
essary for the expression of MCP-1, RANTES, and IP-10 but
not in IL-8, while AP-1 activation may be suﬃcient for expres-
sion of IL-8 but not in MCP-1, RANTES and IP-10 in human
astrocytes. Although expression of IL-8 is dependent on NF-
jB activation in most cases, it has also been reported that
hydrogen peroxide can induce IL-8 expression by AP-1 activa-
tion alone in A549 human lung carcinoma cells but not in hu-
man microvascular endothelial cells [19]. We speculate that the
divergent eﬀect of proteasome inhibitors on chemokine expres-
sion is not restricted to human astrocytes, because we have
also observed that the inhibition of the proteasome pathway
induced IL-8 expression in other cells types, such as human
neuroblastoma cell lines and HeLa cells (unpublished data).
Recently, it was reported that MCP-1 was selectively induced
in murine kidney mesangial cells by the proteasome inhibitors
[5]. These ﬁndings collectively suggest that the expression of
identical molecules such as MCP-1 is diﬀerently regulated
depending on the host or cell type: AP-1 may be suﬃcient to
induce MCP-1 expression in murine kidney mesangial cells
but not in human astrocytic cells.
We demonstrated that inhibition of the proteasome pathway
induced caspase-dependent apoptotic cell death and rendered
cells much more susceptible to the cytotoxic eﬀects of these
cytokines. TNF-a can induce apoptotic cell death by the acti-
vation of caspase cascades, which are suppressed by the over-
riding activation of the NF-jB pathway [20]. IL-1b activates
various signal transduction pathways to induce apoptotic
death, which can also be inhibited by concomitant activation
of NF-jB [21]. Therefore, our results along with previous re-
ports collectively suggest that the proteasome inhibitors might
sensitize cells to apoptosis by suppression of NF-jB activation
(probably along with sustained activation of the JNK/AP-1
pathway).
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